title: [Dolastatins].
authors.affiliation: Laboratoire de pharmacologie antitumorale du Centre Oscar-Lambret et U. 524 Inserm, place de Verdun, 59045 Lille Cedex, France.
authors.forename: A
authors.initials: A
authors.lastname: Lansiaux
authors.forename: C
authors.initials: C
authors.lastname: Bailly
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D017322:Clinical Trials, Phase II as Topic; D047630:Depsipeptides; D006321:Heart / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D009503:Neutropenia / Q000139:chemically induced; D009842:Oligopeptides / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D047630:Depsipeptides; D009842:Oligopeptides; C075610:dolastatin 15; C094621:cemadotin; C064570:dolastatin 10
vernacular_title: Les dolastatines.